Toni Choueiri, MD | Authors


Highlighting Key Trials in Kidney Cancer

June 01, 2019

Toni Choueiri, MD, director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, senior physician, at Dana-Farber Cancer Institute, and Jerome and Nancy Kohlberg Chair and professor of medicine, at Harvard Medical School, highlights key trials in kidney cancer presented at the 2019 ASCO Annual Meeting.

Dr. Toni Choueiri on Nivolumab and Cabozantinib Becoming First-Line Therapies in RCC

January 14, 2016

Choueiri says that while both drugs have a chance to become first-line therapies, nivolumab does more so than cabozantinib. He says there is a phase III study that has recently finish accrual that looks at combining nivolumab and ipilimumab, in comparison to sunitinib, as a treatment for RCC.